SCHEMBL15739072

SCHEMBL15739072

CC1CCN(c2nc(C=CC(=O)O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 14/20 0.46
NTRK1 P04629 1/20 0.38
KIT P10721 1/20 0.38
AXL P30530 1/20 0.38
FLT3 P36888 1/20 0.38
GPR6 P46095 2/20 0.34
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 3/20 0.34
GAA P10253 3/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 2/20 0.33
NPC1 O15118 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
RAB9A P51151 1/20 0.33
CASP7 P55210 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14384938 1.00 CSF1R (0.46) CSF1RNTRK1KITAXLFLT3
SCHEMBL14384929 0.84 CSF1R (0.65) CSF1RNTRK1KITAXLFLT3
SCHEMBL15418024 0.84 CSF1R (0.65) CSF1RNTRK1KITAXLFLT3
SCHEMBL14384936 0.84 CSF1R (0.57) CSF1RNTRK1KITAXLFLT3
SCHEMBL15418129 0.84 CSF1R (0.57) CSF1RNTRK1KITAXLFLT3
SCHEMBL14405154 0.79 CSF1R (0.43) CSF1RNTRK1KITAXLFLT3
SCHEMBL1866872 0.79 CSF1R (0.43) CSF1RNTRK1KITAXLFLT3
SCHEMBL16491629 0.77 CSF1R (0.46) CSF1RNTRK1KITAXLFLT3
SCHEMBL13147872 0.77 ALDH1A1 (0.56) CSF1RNTRK1KITAXLFLT3
SCHEMBL14384995 0.74 CSF1R (0.49) CSF1RNTRK1KITAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
EP-2021329-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-04-13 EP disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885NTRK1 140/4885KIT 114/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885NTRK1 140/4885KIT 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.